Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 8/20 | 0.42 |
| ▸ | CYP24A1 | Q07973 | 4/20 | 0.42 |
| ▸ | CYP27A1 | Q02318 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211818 | 0.86 | METAP1 (0.48) | METAP1CYP26A1CYP24A1CYP27A1CYP19A1 | |
| SCHEMBL17320388 | 0.83 | METAP1 (0.43) | METAP1CYP26A1CYP24A1CYP27A1CYP19A1 | |
| SCHEMBL15904627 | 0.83 | CYP24A1 (0.59) | METAP1CYP26A1CYP24A1CYP27A1CYP19A1 | |
| SCHEMBL24228697 | 0.80 | CYP19A1 (0.57) | CYP19A1 | |
| SCHEMBL18052663 | 0.78 | THRA (0.53) | METAP1CYP26A1CYP24A1CYP27A1CYP19A1 | |
| SCHEMBL8536553 | 0.75 | DGAT1 (0.57) | METAP1CYP26A1CYP24A1CYP27A1CYP19A1 | |
| SCHEMBL17211829 | 0.74 | CYP24A1 (0.44) | METAP1CYP26A1CYP24A1CYP27A1CYP19A1 | |
| SCHEMBL12433392 | 0.71 | ACHE (0.54) | METAP1CYP26A1CYP24A1CYP27A1PARP10 | |
| SCHEMBL17195438 | 0.71 | CYP24A1 (0.46) | METAP1CYP26A1CYP24A1CYP27A1CYP19A1 | |
| SCHEMBL11828763 | 0.70 | PARP10 (0.47) | METAP1CYP26A1CYP24A1CYP27A1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376387-B2 | Oxidisable pyridine derivatives, their preparation and use as anti-alzheimer agents | INSA INST NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2016-06-28 | — | — | US | disclosed |
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | CBR3, CBR1, CYB5R3 | METAP1 4553/4885CYP26A1 506/4885CYP24A1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.